Cargando…

TNF-R1, an immune checkpoint in melanoma?

Detalles Bibliográficos
Autores principales:	Bertrand, Florie, Colacios, Céline, Ségui, Bruno
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4633164/ https://www.ncbi.nlm.nih.gov/pubmed/26622939

Ejemplares similares

TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
por: Bertrand, Florie, et al.
Publicado: (2017)

Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1
por: Imbert, Caroline, et al.
Publicado: (2020)

The TNF Paradox in Cancer Progression and Immunotherapy
por: Montfort, Anne, et al.
Publicado: (2019)

Corrigendum: The TNF Paradox in Cancer Progression and Immunotherapy
por: Montfort, Anne, et al.
Publicado: (2019)

Anti-TNF, a magic bullet in cancer immunotherapy?
por: Montfort, Anne, et al.
Publicado: (2019)

Downregulation of sphingosine kinase-1 induces protective tumor immunity by promoting M1 macrophage response in melanoma
por: Mrad, Marguerite, et al.
Publicado: (2016)

The neurotoxic effects of immune checkpoint inhibitor therapy for melanoma
por: Spain, Lavinia, et al.
Publicado: (2019)

Sphingomyelin Synthase 1 (SMS1) Downregulation Is Associated With Sphingolipid Reprogramming and a Worse Prognosis in Melanoma
por: Bilal, Fatima, et al.
Publicado: (2019)

Immune Checkpoint Inhibitor Therapy: A Boon to Elderly Patients with Advanced Melanoma?
por: Muta, Tsuyoshi
Publicado: (2018)

From checkpoint to checkpoint: DNA damage ATR/Chk1 checkpoint signalling elicits PD-L1 immune checkpoint activation
por: Mouw, Kent W., et al.
Publicado: (2018)

Immune checkpoint inhibitors in penile cancer
por: Buonerba, Carlo, et al.
Publicado: (2021)

TLR2 – an innate immune checkpoint in multiple sclerosis
por: Hossain, Md Jakir, et al.
Publicado: (2015)

Checkpoint blocker induced autoimmunity as an indicator for tumour efficacy in melanoma
por: Hassel, Jessica C.
Publicado: (2021)

Combination strategies incorporating oncolytic viruses and immune checkpoint inhibitors for advanced melanoma: what is the evidence?
por: Wongariyapak, Amarin, et al.
Publicado: (2023)

Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018)

Corticosteroids and immune checkpoint blockade
por: Min, Le, et al.
Publicado: (2015)

Reinvigorating tumour-infiltrating lymphocytes from checkpoint inhibitor resistant melanomas
por: Silva, Inês Pires da, et al.
Publicado: (2018)

Cardiotoxicity Associated with Immune Checkpoint Inhibitors
por: Minegishi, Shintaro, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in Melanoma and HIV Infection
por: Marra, Antonio, et al.
Publicado: (2017)

Efficacy of immune checkpoint inhibitors for in-transit melanoma
por: Nan Tie, Emilia, et al.
Publicado: (2020)

The Role of Immune Checkpoint Blockade in Uveal Melanoma
por: Wessely, Anja, et al.
Publicado: (2020)

Update on Immune Checkpoint Inhibitors for Conjunctival Melanoma
por: Sa, Ho-Seok, et al.
Publicado: (2022)

Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma
por: Fujimura, Taku, et al.
Publicado: (2022)

TNFα and Immune Checkpoint Inhibition: Friend or Foe for Lung Cancer?
por: Benoot, Thomas, et al.
Publicado: (2021)

Immune checkpoint inhibitors in renal cell carcinoma
por: Ross, Kirsty, et al.
Publicado: (2017)

Advanced Research on Immune Checkpoint Inhibitor Therapy
por: Imai, Hisao, et al.
Publicado: (2022)

Lessons from clinical trials on triple combination of immune checkpoint inhibitors and BRAF/MEK inhibitors in BRAF-mutant melanoma
por: Maeda, Takuya, et al.
Publicado: (2023)

Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade
por: Fox, Douglas B., et al.
Publicado: (2023)

TTF-1 and immune checkpoint therapy in non-small cell lung cancer
por: Gumbleton, Matthew, et al.
Publicado: (2023)

Predictors of responses to immune checkpoint blockade in advanced melanoma
por: Jacquelot, N., et al.
Publicado: (2017)

Correction: Efficacy of immune checkpoint inhibitors for in-transit melanoma
Publicado: (2020)

Efficacy of immune checkpoint inhibitors in different types of melanoma
por: Rossi, Ernesto, et al.
Publicado: (2020)

Dermatomyositis Flare With Immune Checkpoint Inhibitor Therapy for Melanoma
por: Thomas, Rachel, et al.
Publicado: (2021)

Landscape and Clinical Significance of Immune Checkpoint in Cutaneous Melanoma
por: Mao, Rui, et al.
Publicado: (2021)

Predictive factors of neoadjuvant immune checkpoint blockade in melanoma
por: Sarver, Melissa, et al.
Publicado: (2021)

Inhibition of myeloperoxidase enhances immune checkpoint therapy for melanoma
por: Liu, Tracy W, et al.
Publicado: (2023)

TIGIT, a novel immune checkpoint therapy for melanoma
por: Tang, Wei, et al.
Publicado: (2023)

HLA-G: A New Immune Checkpoint in Cancer?
por: Krijgsman, Daniëlle, et al.
Publicado: (2020)

Two Types of Immune Checkpoint Inhibitor-related Pancreatitis
por: Ichiki, Tomoko, et al.
Publicado: (2021)

The Emerging Role of NK Cells in Immune Checkpoint Blockade
por: Martinez-Perez, Alejandra, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1n26iirgtipjjgpqdss6e8pd3b